Bafna Pharmaceuticals Ltd
Incorporated in 1981, Bafna Pharmaceuticals
Ltd manufactures finished pharmaceutical formulations[1]
- Market Cap ₹ 189 Cr.
- Current Price ₹ 80.0
- High / Low ₹ 113 / 73.2
- Stock P/E 246
- Book Value ₹ 35.0
- Dividend Yield 0.00 %
- ROCE 9.48 %
- ROE 9.44 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 12.6% over last 3 years.
- Earnings include an other income of Rs.2.68 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
167 | 177 | 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 143 | |
146 | 156 | 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 138 | |
Operating Profit | 21 | 21 | -16 | 3 | -5 | -35 | -13 | 1 | 10 | 12 | 16 | 11 | 6 |
OPM % | 13% | 12% | -16% | 3% | -8% | -77% | -30% | 3% | 14% | 14% | 14% | 7% | 4% |
3 | 1 | 40 | 1 | 1 | 31 | 0 | -23 | 1 | -0 | 3 | 4 | 3 | |
Interest | 11 | 12 | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 |
Depreciation | 8 | 8 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 6 |
Profit before tax | 5 | 2 | 6 | -13 | -19 | -14 | -18 | -25 | 6 | 5 | 12 | 7 | 0 |
Tax % | 25% | 40% | -0% | -3% | -4% | 15% | 8% | 0% | 0% | 0% | 2% | 0% | |
4 | 1 | 6 | -12 | -18 | -16 | -20 | -25 | 6 | 5 | 11 | 7 | 0 | |
EPS in Rs | 2.08 | 0.72 | 3.28 | -6.53 | -9.90 | -6.95 | -8.34 | -106.53 | 2.46 | 2.21 | 4.79 | 3.11 | 0.19 |
Dividend Payout % | 29% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -1% |
5 Years: | 28% |
3 Years: | 29% |
TTM: | -10% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 19% |
3 Years: | 8% |
TTM: | -96% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | % |
3 Years: | -14% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | -17% |
5 Years: | 10% |
3 Years: | 13% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 19 | 19 | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 |
Reserves | 49 | 50 | 53 | 41 | 22 | 17 | -3 | 49 | 33 | 38 | 50 | 57 | 59 |
91 | 99 | 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 19 | |
84 | 54 | 50 | 45 | 44 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 33 | |
Total Liabilities | 243 | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 134 |
66 | 63 | 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 56 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 12 | 2 |
Investments | 1 | 1 | 18 | 18 | 18 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
175 | 158 | 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 77 | |
Total Assets | 243 | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 134 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 1 | 9 | -3 | 14 | -7 | -1 | -34 | -14 | 10 | 5 | 9 | |
-6 | -5 | 56 | -1 | -8 | 38 | 4 | 33 | -5 | -7 | -7 | -15 | |
-11 | -14 | -66 | 4 | -5 | -31 | -2 | 7 | 12 | -5 | 10 | -1 | |
Net Cash Flow | 18 | -18 | -0 | 0 | -0 | 0 | 0 | 6 | -7 | -2 | 8 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 187 | 192 | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 |
Inventory Days | 63 | 78 | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 |
Days Payable | 215 | 116 | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 |
Cash Conversion Cycle | 35 | 155 | 220 | 214 | 255 | 31 | -188 | 31 | 96 | 135 | 94 | 84 |
Working Capital Days | 150 | 204 | 250 | 320 | 207 | 79 | -16 | 89 | 172 | 148 | 150 | 126 |
ROCE % | 9% | 9% | -13% | -0% | -6% | -36% | -21% | -3% | 10% | 11% | 16% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2024 published in "Business Standard" and …
- Unaudited Financial Results For The Quarter Ended 30.09.2024 11 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11/11/2024
11 Nov - Board approved unaudited financial results for Q2 2024.
-
Update on board meeting
4 Nov - Board meeting to approve Q2 financial results.
-
Board Meeting Intimation for Board Meeting Scheduled On November 11, 2024
4 Nov - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1][2][3]
Company is manufacturing over 336
licensed pharmaceutical formulations
and has globally registered 78 of its
products viz. Afenac-p Tab, Afenac-th
Tab, finished solid oral and liquid oral
dosage forms of Betalactam and Non – Betalactam and Cephalosporin products